HOSPITAL MEDICINES LIST RESTRICTIONS CHECKLIST

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Durvalumab	
INITIATION – Non-small cell lung cancer Re-assessment required after 4 months	

o	0	Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC)
	" ()	Patient has histologically or cytologically documented stage IIb (T1N2a only), locally advanced, unresectable non-small cell lung cancer (NSCLC)
and O	Patie	ent has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy
and		ent has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation upy treatment
and O and	Patie	ent has a ECOG performance status of 0 or 1
	Patie	ent has completed last radiation dose within 8 weeks of starting treatment with durvalumab
and _	Patie	ent must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition
	0	Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks
0	0	Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks

CONTINUATION – Non-small cell lung cancer Re-assessment required after 4 months **Prerequisites** (tick boxes where appropriate)

and	_	The treatment remains clinically appropriate and the patient is benefitting from treatment O Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks
	or	O Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks
and (and	С	Treatment with durvalumab to cease upon signs of disease progression
(С	Total continuous treatment duration must not exceed 12 months